Instituto de Investigación Sanitaria Fundación para la Investigación del Hospital Clínico de Valencia-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2024

  1. Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries

    United European Gastroenterology Journal

2023

  1. In the Literature: March 2023

    ESMO Open

  2. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study

    Clinical Colorectal Cancer, Vol. 22, Núm. 1, pp. 100-110

2022

  1. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences

    Clinical Cancer Research, Vol. 28, Núm. 3, pp. 507-517

  2. In the literature: November 2022

    ESMO Open

  3. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma

    British Journal of Cancer, Vol. 127, Núm. 12, pp. 2198-2206

  4. Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients

    Cancers, Vol. 14, Núm. 5

  5. Quality of life in cancer survivorship: Sociodemographic and disease-related moderators

    European Journal of Cancer Care, Vol. 31, Núm. 6

2021

  1. Translational epigenetics in precision medicine of colorectal cancer

    Epigenetics in Precision Medicine (Elsevier), pp. 19-41

2020

  1. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target

    Cancer Treatment Reviews, Vol. 86

2019

  1. Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens

    Histopathology, Vol. 75, Núm. 4, pp. 517-525

  2. Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression

    Modern Pathology, Vol. 32, Núm. 2, pp. 306-313

  3. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 30, Núm. 11, pp. 1804-1812

2018

  1. A multi-omic analysis for prospective patient stratification in localised colorectal cancer (CRC)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii717

  2. NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii224

2016

  1. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology

    Oncotarget, Vol. 7, Núm. 16, pp. 22543-22555